Effect of statins on serum vitamin D concentrations: a systematic review and meta-analysis

European Journal of Clinical Investigation

Volumn 47, Issue 1, 2017, Pages 93-101

  Mazidi, Mohsen ^a,b   Rezaie, Peyman ^c   Vatanparast, Hassan ^d   Kengne, Andre Pascal ^e  

^a INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY   (China)

^b International College   (China)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Meta analysis; statins; vitamin D

Indexed keywords

ATORVASTATIN; ROSUVASTATIN; SIMVASTATIN; VITAMIN D; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

HUMAN; PRIORITY JOURNAL; PUBLISHING; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; VITAMIN BLOOD LEVEL; BLOOD; META ANALYSIS;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; VITAMIN D;

EID: 85006678309     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12698     Document Type: Review

References (44)

1. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007;370:1829–39.
2. Mazidi M, Rokni H, Sahebkar AH, Mohammadi A, Ghayour-Mobarhan M, Ferns GA. Simvastatin treatment does not affect serum vitamin D concentrations in patients with dyslipidemia: a randomized double-blind placebo-controlled cross-over trial. Int J Prev Med 2016;7:80.
3. Athyros VG, Katsiki N, Tziomalos K, Gossios TD, Theocharidou E, Gkaliagkousi E et al. Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. Arch Med Sci 2013;9:418–26.
4. Kowalski J, Barylski M, Banach M, Grycewicz J, Irzmanski R, Pawlicki L. Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention. J Cardiovasc Pharmacol 2006;48:143–7.
5. Reiner Z. Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol 2013;10:453–64.
6. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;(1):Cd004816.
7. Health, United States, 2010: with Special Feature on Death and Dying. Hyattsville, MD: National Center for Health Statistics; 2011.
8. Pencina MJ, Navar-Boggan AM, D'Agostino RB Sr, Williams K, Neely B, Sniderman AD et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med 2014;370:1422–31.
9. Moezzi A, Parizadeh SM, Tavallaie S, Mazidi M, Afzali F, Adab A et al. Effects of simvastatin treatment on serum adiponectin concentrations in patients with dislipidemia. Iran Red Crescent Med J 2014;16:e6915.
10. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 2008;168:1174–80.
11. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266–81.
12. Xu Y, Hashizume T, Shuhart MC, Davis CL, Nelson WL, Sakaki T et al. Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol Pharmacol 2006;69:56–65.
13. Ertugrul DT, Yavuz B, Cil H, Ata N, Akin KO, Kucukazman M et al. STATIN-D study: comparison of the influences of rosuvastatin and fluvastatin treatment on the levels of 25 hydroxyvitamin D. Cardiovasc Ther 2011;29:146–52.
14. Yavuz B, Ertugrul DT, Cil H, Ata N, Akin KO, Yalcin AA et al. Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins? Cardiovasc Drugs Ther 2009;23:295–9.
15. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264–9, W64.
16. Phan K, Tian DH, Cao C, Black D, Yan TD. Systematic review and meta-analysis: techniques and a guide for the academic surgeon. Ann Cardiothorac Surg 2015;4:112–22.
17. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35–53.
18. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.2. London: The Cochrane Collaboration; 2009.
19. Chan YH, Lau KK, Yiu KH, Li SW, Tam S, Lam TH et al. Vascular protective effects of statin-related increase in serum 25-hydroxyvitamin D among high-risk cardiac patients. J Cardiovasc Med (Hagerstown) 2015;16:51–8.
20. Perez-Castrillon JL, Vega G, Abad L, Sanz A, Chaves J, Hernandez G et al. Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol 2007;99:903–5.
21. Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol 2012;65:934–9.
22. Werfalli M, Musekiwa A, Engel ME, Ross I, Kengne AP, Levitt NS. The prevalence of type 2 diabetes mellitus among older people in Africa: a systematic review study protocol. BMJ Open 2014;4:e004747.
23. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005;5:13.
24. Mazidi M, Karimi E, Rezaie P, Ferns GA. Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. J Diabetes Complications 2016; doi:10.1016/j.jdiacomp.2016.05.022.
25. Mazidi M, Gao HK, Rezaie P, Ferns GA. The effect of ginger supplementation on serum C-reactive protein, lipid profile and glycaemia: a systematic review and meta-analysis. Food Nutr Res 2016;60:32613.
26. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for Meta-Analysis in Medical Research. West Sussex, UK: John Wiley & Sons; 2000.
27. Ferretti G, Bacchetti T, Sahebkar A. Effect of statin therapy on paraoxonase-1 status: a systematic review and meta-analysis of 25 clinical trials. Prog Lipid Res 2015;60:50–73.
28. Sahebkar A. Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother Res 2014;28:633–42.
29. Sahebkar A, Serban MC, Mikhailidis DP, Toth PP, Muntner P, Ursoniu S et al. Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: a systematic review and meta-analysis. Pharmacol Res 2016;103:236–52.
30. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455–63.
31. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive Metaanalysis (Vers. 2). Englewood Cliffs, NJ: Biostat. Inc; 2005.
32. Sathyapalan T, Shepherd J, Arnett C, Coady AM, Kilpatrick ES, Atkin SL. Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clin Chem 2010;56:1696–700.
33. Rejnmark L, Vestergaard P, Heickendorff L, Mosekilde L. Simvastatin does not affect vitamin d status, but low vitamin D levels are associated with dyslipidemia: results from a randomised, controlled trial. Int J Endocrinol 2010;2010:957174.
34. Makariou SE, Liberopoulos EN, Agouridis AP, Challa A, Elisaf M. Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels. J Cardiovasc Pharmacol Ther 2012;17:382–6.
35. Liberopoulos EN, Makariou SE, Moutzouri E, Kostapanos MS, Challa A, Elisaf M. Effect of simvastatin/ezetimibe 10/10 mg versus simvastatin 40 mg on serum vitamin D levels. J Cardiovasc Pharmacol Ther 2013;18:229–33.
36. Ekins S, Stresser DM, Williams JA. In vitro and pharmacophore insights into CYP3A enzymes. Trends Pharmacol Sci 2003;24:161–6.
37. Guengerich FP. Cytochrome p450 and chemical toxicology. Chem Res Toxicol 2008;21:70–83.
38. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013;138:103–41.
39. Mauro VF. Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet 1993;24:195–202.
40. Bhattacharyya S, Bhattacharyya K, Maitra A. Possible mechanisms of interaction between statins and vitamin D. QJM 2012;105:487–91.
41. Roche VF. Antihyperlipidemic statins: a self-contained, clinically relevant medicinal chemistry lesson. Am J Pharm Educ 2005;69:546–60.
42. Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med 1995;333:664–5.
43. Nuesch E, Trelle S, Reichenbach S, Rutjes AW, Tschannen B, Altman DG et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ 2010;341:c3515.
44. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000;53:1119–29.